Homepage Top Section1

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), along with Inova Health System, has sponsored the trial. Fostamatinib, which is sold

Under the deal, Scribe Therapeutics and Biogen will develop and commercialise CRISPR-based therapies to treat amyotrophic lateral sclerosis (ALS). X-Editing (XE), which is Scribe’s first technology, is said

FDA has provided the breakthrough therapy status based on data from the BPDCN cohort of the first-in-human study of IMGN632, said ImmunoGen. IMGN632 is a CD123-targeting ADC, which

The deal is valued at around $647m on an enterprise basis, including debt obligations expected to be assumed or repaid net of cash. As per terms of the

Koligo is involved in the development of personalised cell therapies using the cells of the patient. The company already commercialised its first commercial product Kyslecel for the treatment

The company’s investigational new drug application (IND) for the clinical trial will be on partial clinical hold until the regulator receives satisfying answers for the questions. The partial

The scope of the deal comprises technical transfer, and fill and finish manufacture of J&J’s SARS-CoV-2 vaccine candidate. GRAM stated that it is having modern equipment to manufacture

The late-stage trial called ENSEMBLE to be held in multiple countries across three countries will study the safety and efficacy of a single dosage of JNJ-78436735 in comparison

The companies are seeking approval for the use of ide-cel in adult patients with the disease who have been subjected to least three prior therapies. The investigational cell